论文部分内容阅读
肝康颗粒为中国中医研究院广安门医院院内制剂,系肿瘤科知名专家多年临床经验的结晶,主要功能为益气扶正、化瘀解毒、软坚散结,临床用于原发性肝癌的中医药治疗,此外该药尚有明显的止痛作用。实验研究证实,肝康颗粒可以保护肝功能、增强机体免疫能力、阻止和改善肝纤维化的病理过程等。和肝动脉化疗栓塞术(TACE,简称介入治疗)联合治疗原发性肝癌的初步研究显示,肝康颗粒可以提高TACE的疗效,同时还能减轻TACE的毒副反应。为进一步深入了解该中药联合TACE治疗原发性肝癌及保护肝功能的确切效果,以本院肿瘤科为组长单位的课题组已申请到国家中医药管理局课题《肝康颗粒减轻原发性肝癌肝动脉化疗栓塞术后肝功能损害的临床研究》。现诚招肝癌病人入组,介入治疗的同时免费服用试验用药(肝康颗粒),研究周期为1个月,要求为住院患者,病人年龄在18岁～70岁之间。
Gankang granule is the in-hospital preparation of Guang’anmen Hospital of China Academy of Traditional Chinese Medicine, which is the crystallization of many years of clinical experience of renowned experts in oncology. Its main functions are Qi-weizheng, phlegm-resolving, detoxification, and sclerotherapy, and clinically used in primary liver cancer. Treatment, in addition the drug still has a clear analgesic effect. Experimental studies confirmed that Gankang granules can protect liver function, enhance immunity, prevent and improve the pathological process of hepatic fibrosis. Preliminary studies with hepatic arterial chemoembolization (TACE, referred to as interventional therapy) for primary hepatocellular carcinoma (HACE) have shown that gankang granules can improve the efficacy of TACE and at the same time reduce the toxicity of TACE. In order to further understand the exact effect of the combination of traditional Chinese medicine and TACE in the treatment of primary liver cancer and protect liver function, the research group with the oncology department of our hospital has applied for the topic of the National Traditional Chinese Medicine Administration. Clinical study of hepatic arterial chemoembolization after hepatic arterial chemoembolization. Recruitment of patients with liver cancer is now being enrolled in the group. Interventional treatment is free as well as taking experimental drug (Gankang granules) for a period of one month. Patients are required to be hospitalized and patients are between 18 and 70 years of age.